{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:24:54Z","timestamp":1789680294453,"version":"4.0.1"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014114","name":"GW Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS) and CDKL5 deficiency disorder (CDD) are rare epileptic conditions, characterised by drug-resistant seizures. Seizure management in these patients requires careful therapy selection. This targeted literature review (TLR) aimed to collate and synthesise information from country-specific and international treatment guidelines for DS, LGS and CDD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A TLR was performed between 25<jats:sup>th<\/jats:sup> January and 11<jats:sup>th<\/jats:sup> March 2021. Online rare diseases and guideline databases were manually searched in addition to websites of national health technology assessment bodies for the following countries: Australia, Canada, France, Germany, Israel, Italy, Japan, Spain, Switzerland, UK and US, as defined by pre-specified eligibility criteria. Search terms, developed for each condition, were translated into local languages where appropriate. Descriptive analyses were performed to examine the geographical distribution of included guidelines; methodologies used to develop guidelines; cross-referencing of treatment recommendations made within other guidelines; patterns of treatment recommendations. An author map was created using R version 3.5.1, to visualise the extent of collaboration between authors.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Forty total guidelines were included, of which 29, 34 and 0 contained recommendations for DS, LGS and CDD, respectively (some provided recommendations for \u22651 condition). Most were country-specific, with guideline authors predominantly publishing in regional groups. Five guidelines were classified as \u201cInternational\u201d and displayed connections between author groups in the US, UK, France and Italy. Reported guideline development processes were lacking [43% (17 guidelines) had unclear\/absent literature review methodologies] and those reported were variable, including both systematic and targeted literature reviews. Use of expert consultation was also variable. A high degree of heterogeneity was observed in the availability of treatment recommendations across disorders, with 271 and 190 recommendations for LGS and DS, respectively, and contradictory positive and negative treatment recommendations for several drugs in each indication [35% (11\/31) and 22% (6\/27) in LGS and DS, respectively].<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This review highlights the need for further high-quality international consensus-based treatment guidelines for LGS, DS, and particularly for CDD (for which no treatment guidelines were identified). Supra-national consensus guidance based on findings from a wider geographical range may improve resource allocation and establish an improved world-wide standard of care.<\/jats:p>","DOI":"10.3389\/fneur.2021.734612","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T07:02:31Z","timestamp":1635145351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment Guidelines for Rare, Early-Onset, Treatment-Resistant Epileptic Conditions: A Literature Review on Dravet Syndrome, Lennox-Gastaut Syndrome and CDKL5 Deficiency Disorder"],"prefix":"10.3389","volume":"12","author":[{"given":"Richard F.","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mingorance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ruban-Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishan","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Nortvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"501981","DOI":"10.1155\/2013\/501981","article-title":"Diagnosis and management of epileptic encephalopathies in children","volume":"2013","author":"Jain","year":"2013","journal-title":"Epilepsy Res Treat."},{"key":"B2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/ejhg.2012.156","article-title":"The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy","volume":"21","author":"Fehr","year":"2013","journal-title":"Eur J Hum Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.02.015","article-title":"Cyclin-dependent kinase-like 5 deficiency disorder: clinical review","volume":"97","author":"Olson","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B4","unstructured":"CDKL5"},{"key":"B5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10072-017-3188-y","article-title":"Lennox-Gastaut syndrome: a comprehensive review","volume":"39","author":"Asadi-Pooya","year":"2018","journal-title":"Neurol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/brainsci10020107","article-title":"CDKL5 deficiency disorder-a complex epileptic encephalopathy","volume":"10","author":"Jakimiec","year":"2020","journal-title":"Brain Sci"},{"key":"B7","doi-asserted-by":"crossref","unstructured":"Dravet Syndrome.2018","DOI":"10.1111\/dmcn.13778"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1212\/CPJ.0b013e31823d07d1","article-title":"Treating patients with medically resistant epilepsy","volume":"1","author":"Krauss","year":"2011","journal-title":"Neurol Clin Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4137\/JCNSD.S8315","article-title":"Pharmacotherapeutic and non-pharmacological options for refractory and difficult-to-treat seizures","volume":"4","author":"Mitchell","year":"2012","journal-title":"J Cent Nerv Syst Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/pnp.422","article-title":"Pharmacological management of epilepsy","volume":"20","author":"Brown","year":"2016","journal-title":"Prog Neurol Psychiatry"},{"key":"B11","unstructured":"MedlinePlus: Lennox-Gastaut syndrome."},{"key":"B12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jval.2016.08.725","article-title":"Variation in health technology assessment and reimbursement processes in Europe","volume":"20","author":"Akehurst","year":"2017","journal-title":"Value Health."},{"key":"B14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","article-title":"EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation","volume":"13","author":"Detela","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/sj.bjc.6601077","article-title":"Clinical practice guidelines: towards better quality guidelines and increased international collaboration","volume":"89","author":"Grol","year":"2003","journal-title":"Br J Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines international network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0170365-e","DOI":"10.1371\/journal.pone.0170365","article-title":"Clinical practice guidelines for rare diseases: the orphanet database","volume":"12","author":"Pavan","year":"2017","journal-title":"PLoS ONE"},{"key":"B18","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.1186\/1750-1172-7-S2-A12","article-title":"Professional clinical guidelines for rare diseases: methodology","volume":"7","author":"Kremp","year":"2012","journal-title":"Orphanet J Rare Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","article-title":"Potential benefits, limitations, and harms of clinical guidelines","volume":"318","author":"Woolf","year":"1999","journal-title":"BMJ."},{"key":"B20","unstructured":"User Satisfaction Survey of the Orphanet Website.2015"},{"key":"B21","unstructured":"Epilepsies: Diagnosis and Management (CG137).2021"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001770","article-title":"Treatment of infantile spasms","author":"Hancock","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003277.pub3","article-title":"Treatment of lennox-gastaut syndrome","author":"Hancock","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1017\/S2045796011000436","article-title":"What is a cochrane review?","volume":"20","author":"Cipriani","year":"2011","journal-title":"Epidemiol Psychiatr Sci."},{"key":"B25","unstructured":"Diacomit (stiripentol.)2020"},{"key":"B26","unstructured":"EU\/3\/14\/1339: Cannabidiol2019"},{"key":"B27","unstructured":"Diacomit (Stiripentol): Highlights Of Prescribing Information.2018"},{"key":"B28","unstructured":"EPIDIOLEX\u00ae (Cannabidiol) oral solution: Highlights of prescribing information.2018"},{"key":"B29","unstructured":"Stiripentol.2020"},{"key":"B30","unstructured":"BANZEL\u00ae (Rufinamide): Highlights of Prescribing Information.2015"},{"key":"B31","unstructured":"LAMICTAL (Lamotrigine): Highlights of Prescribing Information.2020"},{"key":"B32","unstructured":"Topamax (Topiramate): Highlights Of Prescribing Information2014"},{"key":"B33","unstructured":"SYMPAZANTM (Clobazam): Highlights of Prescribing Information2018"},{"key":"B34","unstructured":"FELBATOL\u00ae (Felbamate): FDA Approved Labeling Text.2012"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/epi.13813","article-title":"Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: experience of >100 patients","volume":"58","author":"Lim","year":"2017","journal-title":"Epilepsia."},{"key":"B36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1684\/epd.2007.0144","article-title":"Treatment of pediatric epilepsy: European expert opinion, 2007","volume":"9","author":"Wheless","year":"2007","journal-title":"Epileptic Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/epi.13057","article-title":"Summary of recommendations for the management of infantile seizures: task force report for the ILAE commission of pediatrics","volume":"56","author":"Wilmshurst","year":"2015","journal-title":"Epilepsia."},{"key":"B38","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1177\/088307380502000101","article-title":"Treatment of pediatric epilepsy: expert opinion, 2005","volume":"20","author":"Wheless","year":"2005","journal-title":"J Child Neurol"},{"key":"B39","unstructured":"Diagnosis And Management Of Epilepsy In Adults.2018"},{"key":"B40","unstructured":"GuerriniR\n            ChiamentiG\n            MugelliA\n            RuggieriM\n            LubranoR\n            ProvincialiL\n          Linee Guida: Epilessie Pediatriche. Associazione Italiana Contro L'epilessia2017"},{"key":"B41","unstructured":"AuvinS\n            H\u00f6hnS\n            Dozi\u00e8res-PuyravelB\n            HirschE\n            LescaG\n            Marie-ConiaE\n          National Protocol for Diagnosis and Care (NPSP) Myoclonic Epilepsy in Infants.2019"},{"key":"B42","unstructured":"Provincial Guidelines for the Management of Medically-Refractory Epilepsy in Adults and Children Who Are Not Candidates for Epilepsy Surgery. Critical Care Services Ontario.2016"},{"key":"B43","unstructured":"SneadC\n            BurneoJ\n            RibaupierreSD\n            Elliot-MillerP.\n            FergusonE\n            GouldL\n          2020"},{"key":"B44","unstructured":"S\u00e1nchez-\u00c1lvarezJ\n            Ruiz-Gim\u00e9nezJ\n            Rold\u00e1n AparicioS\n            Serrano-CastroP\n            Arenas CabreraC\n            Camino Le\u00f3nR\n          Gu\u00eda Andaluza de la Epilepsia 2015: Diagn\u00f3stico y tratamiento de la epilepsia en ni\u00f1os y adultos"},{"key":"B45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fneur.2017.00505","article-title":"Expert opinion on the management of lennox\u2013gastaut syndrome: treatment algorithms and practical considerations","volume":"8","author":"Cross","year":"2017","journal-title":"Front Neurol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1365-2788.2009.01182.x","article-title":"Consensus guidelines into the management of epilepsy in adults with an intellectual disability","volume":"53","author":"Kerr","year":"2009","journal-title":"J Intellect Disabil Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of dravet syndrome: recommendations from a North American consensus panel","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pediatric Neurol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia."},{"key":"B50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13012-018-0763-4","article-title":"The advantages and limitations of guideline adaptation frameworks","volume":"13","author":"Wang","year":"2018","journal-title":"Implementation Science."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12874-017-0468-4","article-title":"What kind of systematic review should I conduct? a proposed typology and guidance for systematic reviewers in the medical and health sciences","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1468-3083.2009.03561.x","article-title":"Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists","volume":"24","author":"Paul","year":"2010","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12874-016-0165-8","article-title":"Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology","volume":"16","author":"Eubank","year":"2016","journal-title":"BMC Med Res Methodol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"i1152","DOI":"10.1136\/bmj.i1152","article-title":"The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines","volume":"352","author":"Brouwers","year":"2016","journal-title":"BMJ."},{"key":"B55","unstructured":"Guidelines.2021"},{"key":"B56","unstructured":"Lennox-Gastaut Syndrome.2017"},{"key":"B57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13023-018-0762-1","article-title":"Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR","volume":"13","author":"Richter","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"B58","unstructured":"FINTEPLA\u00ae (fenfluramine) Oral Solution: Highlights of Prescribing Information.2020"},{"key":"B59","doi-asserted-by":"publisher","first-page":"CD003277","DOI":"10.1002\/14651858.CD003277.pub4","article-title":"Anti-seizure medications for Lennox-Gastaut syndrome","volume":"4","author":"Brigo","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejpn.2017.04.1141","article-title":"Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients","volume":"21","author":"Amin","year":"2017","journal-title":"Hippokratia."},{"key":"B61","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.seizure.2020.12.016","article-title":"Efficacy and tolerability of fenfluramine in patients with dravet syndrome: a systematic review and meta-analysis","volume":"85","author":"Sharawat","year":"2021","journal-title":"Seizure."},{"key":"B62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.14581\/jer.14010","article-title":"Old versus new: why do we need new antiepileptic drugs?","volume":"4","author":"Lee","year":"2014","journal-title":"J Epilepsy Res."},{"key":"B63","unstructured":"Sodium valproate.2019"},{"key":"B64","unstructured":"Topiramate.2019"},{"key":"B65","unstructured":"Zonisamide.2019"},{"key":"B66","unstructured":"Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019)\n            HigginsJ\n            ThomasJ\n            ChandlerJ\n            CumpstonM\n            LiT\n            PageM\n          Cochrane.2019"},{"key":"B67","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","article-title":"Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology and the American Epilepsy Society","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.734612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T07:02:40Z","timestamp":1635145360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.734612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":67,"alternative-id":["10.3389\/fneur.2021.734612"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.734612","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"article-number":"734612"}}